

Africa and Middle East continue to contribute to the double-digit growth in emerging markets reporting EUR568m of sales in the fourth quarter.

Finally, looking at Eastern Europe, Russia and Turkey, this region's growth of 5% was driven by sales mainly in Russia of EUR250m, up 10% and also by Turkey with sales growth of 16% for the quarter.

If we go to slide number 22, we show really how Sanofi is poised to capture future growth in fast growing markets. Our scorecard in emerging markets summarizes key metrics of our leading position and how we will continue to leverage our existing presence in these regions.

Moving from left to right, you can see that Sanofi is the undisputed number one healthcare company in emerging markets with a market share of 5.7%. Our leadership position is well balanced between BRIC and non-BRIC countries. We have a broad and strong presence in these markets in terms of product portfolio, sales forces of over 23,000 people and a very wide network of 37 industrial sites. This really puts us in a unique position to capitalize on ongoing trends related to demographics, urbanization, expansion of the middle class, higher disposable incomes and consequently a strong increase in the demand for healthcare. As we continue to hone our execution strategy in fast-growing markets, we will maximize our growth opportunities in these regions in the years to come.

So if we move to slide number 23, and we look at the other geographies, we can really see also improving sales trend throughout 2013 in the US representing 31% of sales, but also in Western Europe, making up 23% of sales. Specifically I want to highlight the performance in the fourth quarter where both in the US and Europe, we have returned to growth.

So with that, I will turn over to Pascale to discuss diabetes and CHC business performance.

Pascale Witz - Sanofi SA - EVP, Global Divisions & Strategic Commercial Development

Thank you, Peter. So, let's start with diabetes on slide 24 where we see the Lantus impressive performance showing yet another year of double-digit growth reaching sales of EUR5.7b in 2013. Lantus is clearly the first choice for insulin therapy.

With over 8m patients worldwide, more than 10 years of clinical experience and extensive cardiovascular safety data, Lantus reported its 12th consecutive quarter of growth in Q4 2013 with sales up 20%. Part of this success is supported by the conversion over to the SoloSTAR pen which now represents 58% of the US sales and the majority of the sales in Europe. Our other innovative pen solutions contributed to the success of Lantus in other geographies.

So turning on to Lyxumia on slide 25, we reiterate the key benefits of our once-daily prandial GLP-1 Lyxumia which complements basal insulin. Lyxumia has a pronounced postprandial glucose lowering effect and a limited risk of hypoglycemia. It can be used in combination with overall therapies and with basal insulin. It is now commercially available in several countries including Germany, UK, Spain, Japan and Mexico and we're encouraged by its initial market uptake. So as for the US, we continue to expect to resubmit our NDA to the FDA in 2015 after completion of the ELIXA cardiovascular outcome trial.

Turning on to slide 26, where we look at another of our growth platforms with consumer healthcare. We are the third largest consumer healthcare player in a large but clearly fragmented OTC market. Q4 sales were up 6.1% reaching EUR722m. For the full year, total sales were EUR3b, up 5% driven by the growth in the US and in emerging markets.

Our top seven brands today account for 40% of total sales. And very recently, we have been busy preparing for the launch of Nasacort OTC in the US, which occurred this week, right in time for the spring allergy season. Nasacort OTC 24 hours will be the first and only nasal spray in its class to be available without a prescription.

With that, I will turn it over to Olivier Charmeil to review the vaccines business.